

Pharmaceutical Systems Division

April 1, 2005

Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852

RE: Docket No. 2005N-0036, "Use of Color on Pharmaceutical Product Labels, Labeling and Packaging; Public Hearing"

To Whom It May Concern:

Representatives from West Pharmaceutical Services, Inc. (West) attended the March 7, 2005 public hearing on the Use of Color on Pharmaceutical Product Labels, Labeling and Packaging on the campus of the National Institutes of Health, Bethesda, MD.

West believes that the use of color for differentiation and possible anti-counterfeiting measures for drugs is a useful tool for certain applications and/or specific drug classifications. West supports the opinion that the use of color on pharmaceutical packaging demonstrates an improvement in patient care by adding a secondary layer of protection in the identification, classification and differentiation of drug products. Color differentiation may make the package or information on the package (like cautionary statements, dosage strength, etc.) stand out, be more conspicuous, more obvious, etc.

As a leader in the pharmaceutical closure and primary drug packaging industry, West feels that its expertise could add valuable input to this subject. West could also assist in understanding and determining the feasibility of certain recommendations. If the Agency decides to develop a working group to pursue further action on this topic, West would like to request the opportunity to participate.

Please contact me at (610) 594-2931 or via email at david.weiser@westpharma.com if the Agency decides to move forward on this topic and I will supply you with the name(s) of West person(s) that would like to participate.

Sincerely

David J. Weiser, M.S.

Supervisor, Regulatory Affairs

CC:

E. Keirstead

C. Mooney

B. O'Dell

D. Thomas

0